前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描对前列腺癌挽救性放疗管理的影响:前瞻性多中心随机3期试验(PSMA-SRT NCT03582774)结果
这项前瞻性随机对照3期试验将193例根治性前列腺切除术后生化复发患者随机分为对照组(n=90)和PSMA-PET/CT组(n=103),评估PSMA-PET对挽救性放疗计划的影响。结果显示,PSMA-PET组主要管理改变频率为45%(46/102),对照组为22%(17/76),差异23%(95%CI 9-35%,p=0.002);治疗升级频率分别为29%(30/102)和12%(9/76),差异17.6%(95%CI 5.4-28.5%,p=0.005)。
要点
- PSMA-PET组主要管理改变频率45%(46/102),对照组22%(17/76),差异23%(95%CI 9-35%,p=0.002)。
- PSMA-PET组治疗升级频率29%(30/102),对照组12%(9/76),差异17.6%(95%CI 5.4-28.5%,p=0.005)。
- PSMA-PET在38/102(37%)患者中定位复发:9/102(9%)盆腔外(M1),16/102(16%)盆腔淋巴结(N1),13/102(13%)仅前列腺床。
核心结论
- 在这项前瞻性随机3期研究中,PSMA-PET发现促使33/102(33%)患者发生挽救性放疗计划的重大管理改变。
- 主要终点的最终结果计划于2025年公布,可能提供这些改变是否改善结局的证据。
研究设计与样本
- 前瞻性随机对照3期临床试验,2018年6月至2020年8月随机193例根治性前列腺切除术后生化复发的前列腺癌患者。
- 对照组(n=90)直接进行挽救性放疗,研究组(n=103)在挽救性放疗计划前接受PSMA-PET/CT扫描。
- 两组均允许使用任何其他已批准的影像学方法(包括fluciclovine-PET)。
- 本次分析为次要终点分析:PSMA-PET对挽救性放疗计划的影响。
主要发现
- 实际执行的挽救性放疗计划在178/193(92.2%)患者中可获得:对照组76/90(84.4%),PSMA-PET组102/103(99%)。
- 入组时中位前列腺特异性抗原水平:对照组0.30 ng/ml(IQR 0.19-0.91),PSMA-PET组0.23 ng/ml(IQR 0.15-0.54)。
- 对照组33/76(43%)使用了fluciclovine-PET。
- PSMA-PET在38/102(37%)患者中定位复发:9/102(9%)盆腔外(M1),16/102(16%)盆腔淋巴结(N1,伴或不伴局部复发),13/102(13%)仅前列腺床。
- 主要管理改变频率:对照组22%(17/76) vs PSMA-PET组45%(46/102),差异23%(95%CI 9-35%,p=0.002)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Both imaging and several prognostic factors inform the planning of salvage radiotherapy (SRT). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can localize disease unseen by other imaging modalities. The main objective of the study was to evaluate the impact of PSMA-PET on biochemical recurrence-free survival rate after SRT. METHODS: This prospective randomized, controlled, phase 3 clinical trial randomized 193 patients with biochemical recurrence of prostate cancer after radical prostatectomy to proceed with SRT (control arm, n = 90) or undergo a PSMA-PET/computed tomography (CT) scan prior to SRT planning (investigational arm, n = 103) from June 2018 to August 2020. Any other approved imaging modalities were allowed in both arms (including fluciclovine-PET). This is a secondary endpoint analysis: impact of PSMA-PET on SRT planning. Case-report forms were sent to referring radiation oncologists to collect the management plans before randomization and after completion of SRT. The relative frequency (%) of management changes within each arm were compared using chi-square and Fisher's exact tests. KEY FINDINGS AND LIMITATIONS: The delivered SRT plan was available in 178/193 patients (92.2%;76/90 control [84.4%] and 102/103 PSMA-PET [99%]). Median prostate-specific antigen levels at enrollment was 0.30 ng/ml (interquartile range [IQR] 0.19-0.91) in the control arm and 0.23 ng/ml (IQR 0.15-0.54) in the PSMA-PET arm. Fluciclovine-PET was used in 33/76 (43%) in the control arm. PSMA-PET localized recurrence(s) in 38/102 (37%): nine of 102 (9%) outside of the pelvis (M1), 16/102 (16%) in the pelvic LNs (N1, with or without local recurrence), and 13/102 (13%) in the prostate fossa only. There was a 23% difference (95% confidence interval [CI] 9-35%, p = 0.002) of frequency of major changes between the control arm (22% [17/76]) and the PSMA-PET intervention arm (45%[46/102]). Of the major changes in the intervention group, 33/46 (72%) were deemed related to PSMA-PET. There was a 17.6% difference (95% CI 5.4-28.5%, p = 0.005) of treatment escalation frequency between the control arm (nine of 76 [12%]) and the intervention arm (30/102 [29%]). Treatment de-escalation occurred in the control and intervention arms in eight of 76 (10.5%) and 12/102 (11.8%) patients, and mixed changes in zero of 76 (0%) and four of 102 (3.9%) patients, respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this prospective randomized phase 3 study, PSMA-PET findings provided information that initiated major management changes to SRT planning in 33/102 (33%) patients. The final readout of the primary endpoint planned in 2025 may provide evidence on whether these changes result in improved outcomes. PATIENT SUMMARY: Prostate-specific membrane antigen positron emission tomography leads to management changes in one-third of patients receiving salvage radiotherapy for post-radical prostatectomy biochemical recurrence of prostate cancer.
引用
- Armstrong WR, Kishan AU, Booker KM, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024. PMID: 38290964. doi:10.1016/j.eururo.2024.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。